-
公开(公告)号:US20240197703A1
公开(公告)日:2024-06-20
申请号:US18144737
申请日:2023-05-08
申请人: PFIZER INC.
发明人: Joyann Barber , Sujin Cho-Schultz , Matthew L. Del Bel , Rebecca Anne Gallego , Mingying He , Mehran Jalaie , Robert Steven Kania , Michele Ann McTigue , Sajiv Krishnan Nair , Anne-Marie Dechert Schmitt , Jamison Bryce Tuttle , Dahui Zhou , Ru Zhou
IPC分类号: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
CPC分类号: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
摘要: This invention relates to compounds of general Formula I
and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.-
公开(公告)号:US11684616B2
公开(公告)日:2023-06-27
申请号:US17246551
申请日:2021-04-30
申请人: PFIZER INC.
发明人: Joyann Barber , Sujin Cho-Schultz , Matthew L. Del Bel , Rebecca Anne Gallego , Mingying He , Mehran Jalaie , Robert Steven Kania , Michele Ann McTigue , Sajiv Krishnan Nair , Anne-Marie Dechert Schmitt , Jamison Bryce Tuttle , Dahui Zhou , Ru Zhou
IPC分类号: C07D471/04 , C07D519/00 , A61K31/444 , A61K45/06
CPC分类号: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
摘要: This invention relates to compounds of general Formula I
and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.-
公开(公告)号:US20220401424A1
公开(公告)日:2022-12-22
申请号:US17246551
申请日:2021-04-30
申请人: PFIZER INC.
发明人: Joyann Barber , Sujin Cho-Schultz , Matthew L. Del Bel , Rebecca Anne Gallego , Mingying He , Mehran Jalaie , Robert Steven Kania , Michele Ann McTigue , Sajiv Krishnan Nair , Anne-Marie Dechert Schmitt , Jamison Bryce Tuttle , Dahui Zhou , Ru Zhou
IPC分类号: A61K31/444 , A61K45/06 , C07D519/00 , C07D471/04
摘要: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
-
-